(VIANEWS) – Medpace Holdings (MEDP), West Pharmaceutical (WST), Core Laboratories N.V. (CLB) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Medpace Holdings (MEDP)

24.1% sales growth and 27.3% return on equity

Medpace Holdings, Inc. offers clinical-based medical device and drug development services throughout North America, Europe, Asia, and the Middle East.

Medpace Holdings’s sales growth this year is anticipated to be 23.5% and 13% for next year.

Year-on-year quarterly revenue growth grew by 27.3%, now sitting on 1.21B for the twelve trailing months.

Volume

Today’s last reported volume for Medpace Holdings is 417537 which is 35.76% above its average volume of 307547.

Medpace Holdings’s sales growth for the next quarter is 24.1%. The company’s growth estimates for the current quarter and the next is 25.5% and 10.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.3%.

Volatility

Medpace Holdings’s last day, last week, and last month’s current intraday variation average was 0.31%, 2.19%, and 2.11%, respectively.

Medpace Holdings’s highest amplitude of average volatility was 4.46% (day), 3.79% (last week), and 3.98% (last month), respectively.

Medpace Holdings’s Stock Yearly Top and Bottom Value

Medpace Holdings’s stock is valued at $138.02 at 11:22 EST, way under its 52-week high of $231.00 and higher than its 52-week low of $126.94.

Medpace Holdings’s Moving Average

Medpace Holdings’s value is below its 50-day moving average of $144.25 and way under its 200-day moving average of $176.72.

2. West Pharmaceutical (WST)

21.2% sales growth and 28.54% return on equity

West Pharmaceutical Services, Inc. produces and sells systems that contain and deliver injectable medicines and other healthcare products throughout the United States, Germany, Ireland, France, Ireland, France, Spain, Italy, Germany, France, Germany, Ireland, France, The United Kingdom, as well as internationally.

West Pharmaceutical’s sales growth this year is anticipated to be 30.4% and 8% for next year.

Year-on-year quarterly revenue growth grew by 37.3%, now sitting on 2.52B for the twelve trailing months.

Volume

Today’s last reported volume for West Pharmaceutical is 38749 which is 91.35% below its average volume of 448400.

West Pharmaceutical’s sales growth for the next quarter is 21.2%. The company’s growth estimates for the ongoing quarter and the next is 56.5% and 41.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.54%.

Volatility

West Pharmaceutical’s last day, last week, and last month’s current intraday variation average was 0.10%, 0.86%, and 2.04%, respectively.

West Pharmaceutical’s highest amplitude of average volatility was 2.20% (day), 2.07% (last week), and 2.67% (last month), respectively.

West Pharmaceutical’s Stock Yearly Top and Bottom Value

West Pharmaceutical’s stock is valued at $295.36 at 11:22 EST, way below its 52-week high of $475.35 and way higher than its 52-week low of $253.85.

West Pharmaceutical’s Moving Average

West Pharmaceutical’s value is way below its 50-day moving average of $424.37 and way below its 200-day moving average of $379.25.

3. Core Laboratories N.V. (CLB)

11.8% sales growth and 6.51% return on equity

Core Laboratories N.V. offers products and services to enhance the production of oil and natural gas in America, Canada and around the world.

Core Laboratories N.V.’s sales growth this year is expected to be 11.4% and 16.6% for next year.

Year-on-year quarterly revenue growth grew by 6.4%, now sitting on 477.17M for the twelve trailing months.

Volume

Today’s last reported volume for Core Laboratories N.V. is 899948 which is 85.88% above its average volume of 484155.

Core Laboratories N.V.’s sales growth for the next quarter is 11.8%. The company’s growth estimates for the present quarter and the next is a negative 6.7% and 37.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.51%.

Volatility

Core Laboratories N.V.’s last day, last week, and last month’s current intraday variation average was 7.62%, 5.53%, and 3.43%, respectively.

Core Laboratories N.V.’s highest amplitude of average volatility was 9.93% (day), 7.89% (last week), and 5.65% (last month), respectively.

Core Laboratories N.V.’s Stock Yearly Top and Bottom Value

Core Laboratories N.V.’s stock is valued at $20.09 at 11:22 EST, way below its 52-week high of $44.35 and above its 52-week low of $20.04.

Core Laboratories N.V.’s Moving Average

Core Laboratories N.V.’s value is way under its 50-day moving average of $27.19 and way below its 200-day moving average of $27.24.

4. STORE Capital Corporation (STOR)

9.7% sales growth and 5.79% return on equity

STORE Capital Corporation, an internal net-lease investment trust or REIT that manages real estate, is the market leader in single tenant operational real estate acquisition, management, and investment. It is also the inspiration behind its name.

STORE Capital Corporation’s sales growth this year is expected to be 9.8% and 8.3% for next year.

Year-on-year quarterly revenue growth grew by 20.9%, now sitting on 821.89M for the twelve trailing months.

Volume

Today’s last reported volume for STORE Capital Corporation is 531056 which is 82.11% below its average volume of 2969180.

STORE Capital Corporation’s sales growth for the next quarter is 9.7%. The company’s growth estimates for the ongoing quarter and the next is 13% and negative -7.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.79%.

Volatility

STORE Capital Corporation’s last day, last week, and last month’s current intraday variation average was 1.06%, 1.81%, and 1.59%, respectively.

STORE Capital Corporation’s highest amplitude of average volatility was 2.46% (day), 3.03% (last week), and 2.58% (last month), respectively.

STORE Capital Corporation’s Stock Yearly Top and Bottom Value

STORE Capital Corporation’s stock is valued at $26.05 at 11:22 EST, way below its 52-week high of $37.13 and above its 52-week low of $24.48.

STORE Capital Corporation’s Moving Average

STORE Capital Corporation’s value is under its 50-day moving average of $27.64 and way below its 200-day moving average of $31.32.

5. Target Corporation (TGT)

8% sales growth and 45.98% return on equity

Target Corporation is a retailer of general merchandise in the United States.

Target Corporation’s sales growth this year is anticipated to be 11.7% and 1.7% for next year.

Year-on-year quarterly revenue growth grew by 9.5%, now sitting on 100.33B for the twelve trailing months.

Volume

Today’s last reported volume for Target Corporation is 1018760 which is 83.57% below its average volume of 6201060.

Target Corporation’s sales growth is a negative 0% for the present quarter and 8% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 0.4% and 6.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 45.98%.

Volatility

Target Corporation’s last day, last week, and last month’s current intraday variation average was 2.76%, 3.17%, and 2.56%, respectively.

Target Corporation’s highest amplitude of average volatility was 2.91% (day), 3.00% (last week), and 3.39% (last month), respectively.

Target Corporation’s Stock Yearly Top and Bottom Value

Target Corporation’s stock is valued at $142.52 at 11:22 EST, way below its 52-week low of $166.82.

Target Corporation’s Moving Average

Target Corporation’s value is way under its 50-day moving average of $248.22 and way under its 200-day moving average of $233.69.

LEAVE A REPLY

Please enter your comment!
Please enter your name here